We Create Medicines to Treat Inflammatory Diseases: Adiso Announces Groundbreaking Research Highlighting ADS024 a Novel Oral Agent for Neuroinflammation - EIN Presswire (einnews.com)
Adiso Therapeutics
Biotechnology Research
Concord, Massachusetts 2,196 followers
Advancing Novel Therapies for Inflammatory Diseases
About us
At Adiso, we create medicines to treat inflammatory diseases, improving the lives of patients and their families. Current treatment paradigms are far too often either inadequate to halt disease progression or burden the patient with significant safety concerns. To tackle these challenges, we are advancing an innovative pipeline of small molecules and single strain live biotherapeutic products (SS-LBP) both with novel mechanisms of action. ADS024 (SS-LBP) is currently being evaluated in a Phase 1b study for the prevention of recurrent CDI and a Phase 2 study in mild-to-moderate ulcerative colitis (UC). ADS051 is currently enrolling a Ph1b study in moderate-to-severe ulcerative colitis (UC). Adiso is also developing a novel dual inflammasome inhibitor in discovery phase which is being initially explored in respiratory inflammation, with multiple future therapeutic areas to pursue.
- Website
-
http://adisotx.com
External link for Adiso Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Concord, Massachusetts
- Type
- Privately Held
- Founded
- 2022
Locations
-
Primary
Get directions
Concord, Massachusetts 01742, US
-
Get directions
Hopewell, New Jersey 08525, US
Employees at Adiso Therapeutics
Updates
-
The Adiso Therapeutics team is thrilled to announce its latest ADS024 publication. ADS024, a oral single strain live biotherapeutic product (SS-LBP). Demonstrated in vivo results of LPA3 agonism a novel and differentiated mechanism of action (MOA). Agonism of LPA3 attenuates a fundamental underlying process in neurodegenerative diseases, establishing for the first time that an orally dosed SS-LBP can modulate neurodegenerative disease-related outcomes via its production of a GPCR agonist. This research highlights the potential role of ADS024 as a prophylaxis or treatment for a range of neuroinflammatory diseases, which include Multiple Sclerosis, Parkinson's, Fredricks Ataxia, and Huntington’s Disease. APC Microbiome Ireland, SFI Research Centre, #PD, #MS, #FA, #HD, #Patientsfirst, #neuroinflammation, #CNS @BrainBehavImm
-
-
Adiso Therapeutics reposted this
Adiso Therapeutics/MRS funded PhD candidate at The University of Edinburgh investigating inflammation and tissue regeneration (Rossi/Lucas Labs)
From the 26-28th of June, myself and many others attended the 9th European Workshop on Lipid Mediators #EWLM, hosted by The University of Edinburgh. It was an interesting and exciting conference focused around lipid-based medicinal treatments, which also allowed me to discuss future steps within the field with lipid experts. To top off my experience, I won the Larodan poster prize for my work based on LTB4 and the cannabinoids (bioactive lipids without SPMs). This award was very kindly sponsored by Larodan AB. I would like to thank the organisers, sponsors, and colleagues for a wonderful experience. I would also like to extend thanks to Adiso Therapeutics and Medical Research Scotland for supporting my project. https://lnkd.in/e9FUHFqJ
-
-
Adiso is keeping #patientsfirst by working to shape a brighter future free from the burden of inflammatory disease. Listen to our recent conversation with Rahul Chaturvedi of the Biotech2050 podcast. https://t.ly/lF_JG #Leadership #IBD #ulcerativecolitis
Are you prepared to explore the realm of biotech innovations and evolving industry dynamics? Join host Rahul Chaturvedi in the latest episode of the Biotech2050 podcast with Scott Megaffin, CEO of Adiso Therapeutics, as they discuss differentiation and collaboration in the biotech industry Listen to the episode: https://t.ly/lF_JG
-
-
We look forward to participating in the virtual Canaccord Genuity Group Inc. Inflammatory Bowel Disease Symposium this Wednesday. Tune in to the “Emerging Novel Targets in IBD” panel to hear Adiso CEO Scott Megaffin discuss our highly differentiated and distinct approach to treating #inflammatorydiseases. #IBD #ulcerativecolitis
-
-
From the Adiso team to you, have a safe and happy #holidayseason. As we approach the new year, we’d like to reflect on our 2023 milestones and express gratitude to all who have contributed to our achievements. May your time with friends and family be filled with joy.
-
Connect with Adiso at #BiotechShowcase in San Francisco next month! Get in touch with us directly at [email protected] or through the partnering platform to schedule a meeting: https://bit.ly/3thApub #Inflammatorydisease #Ulcerativecolitis #Biotech
-
-
Adiso Therapeutics reposted this
Adiso is pleased to announce a Precision Immunology collaboration with Geneoscopy to investigate new ADS051 therapeutic benefits in patients with inflammatory bowel disease. The collaboration will employ noninvasive #RNA technology developed by Geneoscopy as a precision #immunology measure in an upcoming ADS051 Phase 2 trial for #IBD. ADS051 is a first-in-class, oral, gut-restricted, small molecule modulator of neutrophil trafficking and activation being developed by Adiso for the treatment of IBD. Read the release: https://bit.ly/3TbtFJ0
-
Adiso is pleased to announce a Precision Immunology collaboration with Geneoscopy to investigate new ADS051 therapeutic benefits in patients with inflammatory bowel disease. The collaboration will employ noninvasive #RNA technology developed by Geneoscopy as a precision #immunology measure in an upcoming ADS051 Phase 2 trial for #IBD. ADS051 is a first-in-class, oral, gut-restricted, small molecule modulator of neutrophil trafficking and activation being developed by Adiso for the treatment of IBD. Read the release: https://bit.ly/3TbtFJ0
-
Today kicks off Crohn’s & Colitis Awareness Week. Year-round, we are dedicated to advancing research and development of novel therapies for patients with #ulcerativecolitis and other #inflammatorydiseases. Read about our progress: https://bit.ly/47RLUao #IBDVisible
-